Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aveo Pharmaceuticals has announced that the US Patent and Trademark Office has granted patent covering the company's mammalian second site suppressor screen technology for identifying small molecule and antibody targets functionally relevant to cancer cell proliferation and survival.
Subscribe to our email newsletter
This patent adds to the intellectual property surrounding Aveo’s proprietary and cancer biology platform.
Tuan Ha-Ngoc, president and CEO of Aveo, said: “We are very pleased to receive this patent recognizing Aveo’s mammalian second site suppressor screen (MaSS) screen technology, the cornerstone of our unique biology platform, and our innovative work in antibody and small molecule target identification for cancer.”